INBX

Inhibrx Biosciences, Inc.

NASDAQ: INBX · HEALTHCARE · BIOTECHNOLOGY

$87.75

-3.14% today

Updated 2026-11-12

Market cap

$1.33B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-8.89

Dividend yield

—

52W range

$57 – $155

Volume

0.3M

Market cap

$1.33B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-8.89

Dividend yield

—

52W range

$57 – $155

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-4.4

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →259 stocks currently score above 75

Price targets

Analyst target

$266.67

+203.91%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity -0.10x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -4.38 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-29.94M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$2.19M	$1.80M	$200000.00	$1.30M	$0.00
Net income	$-145.23M	$-241.36M	$1.69B	$-140.06M	$-36.65M
EPS	—	—	—	—	$-8.89
Free cash flow	$-115.99M	$-197.90M	$-197.01M	$-129.82M	$-29.94M
Profit margin	-6,625.27%	-13,408.94%	843,786.00%	-10,773.46%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
INBX	$1.33B	21	2.7	3.0	5.0	6.5	—	Avoid
LLY	$1.26T	74	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$657.68B	54	4.7	8.5	3.7	5.5	—	Buy
ABBV	$521.11B	77	6.7	9.0	4.0	5.0	-85.21%	Strong Buy
MRK	$368.89B	44	3.3	6.5	2.0	5.0	-72.89%	Hold
UNH	$365.29B	62	6.7	6.0	4.7	5.5	-20.81%	Buy

Smart narrative

Inhibrx Biosciences, Inc. trades at $87.75. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -4.38, it sits in the distress.

Frequently asked questions

What is Inhibrx Biosciences, Inc.'s stock price?

Inhibrx Biosciences, Inc. (INBX) trades at $87.75.

Is Inhibrx Biosciences, Inc. overvalued?

Inhibrx Biosciences, Inc. carries a Smart Value Score of 21/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Inhibrx Biosciences, Inc. (INBX)?

The 12-month analyst consensus target is $266.67, about 203.9% above the current $87.75. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Inhibrx Biosciences, Inc.'s Altman Z-Score is -4.38, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-354.70%

Beta4.04

50D MA$97.47

200D MA$92.48

Shares out0.01B

Float0.01B

Short ratio—

Avg volume0.3M

Performance

1 week+19.24%

1 month+9.31%

3 months+3.97%

YTD-4.11%

1 year—

3 years—

5 years—

Compare

INBX vs LLY →INBX vs JNJ →INBX vs ABBV →Stock screener →